Preparation method of pitobubrutinib

The preparation process of pitobrutinib is simplified by reacting nitro of sodium hydroxide and hydrogen peroxide with carboxylic acid in one step, combining Pd(dppf)Cl2, inorganic salts and NaOH, H2O2 and other reactants, and solving the existing technology The problems of high operational risk and numerous steps have achieved efficient and simple synthesis methods, which are suitable for industrial production.

CN119059974AActive Publication Date: 2024-12-03WUHAN JIUZHOU YUMIN PHARM TECH CO LTD
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
CN202411100888.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-12
Publication Date
2024-12-03
Estimated Expiration
2044-08-12

AI Technical Summary

Technical Problem

The existing preparation method of pitobrutinib has problems such as high operational risk and numerous steps, and the yield and purification process are complex, making it difficult to meet the needs of industrial production.

Method used

Sodium hydroxide and hydrogen peroxide are used to react nitro and carboxylic acid in one-step. Combined with Pd(dppf)Cl2, inorganic salts, NaOH, H2O2 and other reactants, and directly synthesize piratro through Suzuki coupling reaction and oxidation reaction under alkaline environment. Brutinib, simplifies reaction steps and reduces operational risk.

Benefits of technology

It realizes the efficient preparation of pitobrutinib, with high yield, simple purification, simple operation, suitable for industrial production, reduces the risk of operation in the reaction, reduces steps, and improves synthesis efficiency.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004989342350000011
    Figure BDA0004989342350000011
  • Figure BDA0004989342350000021
    Figure BDA0004989342350000021
  • Figure BDA0004989342350000071
    Figure BDA0004989342350000071
Patent Text Reader

Abstract

The invention relates to a preparation method of pitobubrutinib. According to the preparation method disclosed by the invention, three-step reaction is carried out, sodium hydroxide and hydrogen peroxide are adopted in a route, and the operation risk in the reaction is reduced; besides, the nitro group of the compound shown in the formula 4 and the carboxylic acid of the compound shown in the formula 5 are subjected to one-step reaction to generate the product, and compared with a method in which the nitro group is firstly converted into an amino group and then reacts with the carboxylic acid, the method has the advantage that the reaction steps are reduced while the yield is kept unchanged. The preparation method has the advantages of simplicity in operation, high yield, simplicity and convenience in purification and the like.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedicine technology, and in particular to a method for preparing pitobrutinib. Background Art

[0002] Pirtobrutinib (also known as Pirtobrutinib, R&D code: LOXO-305, trade name: Jaypirca) is a small molecule BTK inhibitor. On January 27, 2023, Eli Lilly announced that the U.S. FDA accelerated the approval of its new generation BTK inhibitor, Pirtobrutinib, for adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have received at least two lines of systemic treatment (including BTK inhibitors). Pirobrutinib is also the first and so far the only non-covalent (reversible) BTK inhibitor approved by the U.S. FDA. The previously marketed BTK small molecule inhibitors are all covalent BTK inhibitors, which mainly produce enzyme inhibition by forming covalent bonds with cysteine ​​residues in the BTK active site, but covalent binding is prone to drug-resistant mutations. Pirobrutinib can reestablish BTK inhibition in MCL patients who have previously been treated with covalent BTK inhibitors (ibrutinib, acalabrutinib, or zanubrutinib).

[0003] The chemical structure of Pitobrutinib is shown in Formula I:

[0004]

[0005] However, the current preparation method for pirobrutinib still needs to be improved. Summary of the invention

[0006] The present invention aims to solve one of the technical problems in the related art at least to a certain extent. To this end, one object of the present invention is to provide a method for preparing a compound of formula I, Pitobrutinib. Compared with the prior art, the preparation method described in the present invention uses sodium hydroxide and hydrogen peroxide in its route, which reduces the danger of operation in the reaction, and reacts the nitro group with the carboxylic acid in one step to generate the product, while the yield remains unchanged, and the reaction steps are reduced. This route has the advantages of simple operation, high yield, and simple purification, and has great advantages over the previous synthetic routes.

[0007] In one aspect of the present invention, the present invention provides a method for preparing the compound Pitobrutinib represented by Formula I. According to an embodiment of the present invention, the preparation method comprises:

[0008] (1) The compound represented by Formula 1, the compound represented by Formula 2, Pd(dppf)Cl 2 , an inorganic salt A, so as to obtain a compound represented by formula 3;

[0009] (2) The compound shown in Formula 3 is reacted with NaOH, H 2 O 2 Contacting to obtain the compound represented by formula 4;

[0010] (3) contacting the compound represented by Formula 4 and the compound represented by Formula 5 with carbon disulfide and DBU to obtain the compound represented by Formula I, Pitobrutinib,

[0011]

[0012] The inventors found that, using the preparation method of the present invention, with the compound represented by Formula 1 and the compound represented by Formula 2 as starting materials, a total of three steps of reaction can be performed to successfully synthesize and prepare the target product, Pitobrutinib.

[0013] The term "contact" as used herein should be understood in a broad sense, and can be any manner that allows at least two reactants to undergo a chemical reaction, such as mixing the two reactants under appropriate conditions. If necessary, the reactants to be contacted can be mixed under stirring, and thus, the type of stirring is not particularly limited, and can be mechanical stirring, i.e. stirring under the action of mechanical force.

[0014] In this document, the terms "first" and "second" are used for descriptive purposes only and should not be understood as indicating or implying relative importance or implicitly indicating the number of the indicated technical features. Thus, a feature defined as "first" or "second" may explicitly or implicitly include one or more of the features. In the description of the present invention, the meaning of "plurality" is two or more, unless otherwise clearly and specifically defined.

[0015] According to an embodiment of the present invention, the method for preparing the compound represented by Formula 3, the compound represented by Formula 4, and the compound represented by Formula I may also have at least one of the following additional technical features:

[0016] According to an embodiment of the present invention, the chemical reaction of the present invention can be carried out according to any method known in the art. The source of the raw materials of the compound shown in Formula 3, the compound shown in Formula 4, and the compound shown in Formula I is not particularly limited, and it can be prepared by any known method or commercially available. For example, the cas of the compound shown in Formula 1 is: 2764851-21-8.

[0017] According to an embodiment of the present invention, in step (1), the compound represented by formula 1, the compound represented by formula 2, Pd(dppf)Cl 2 The contacting method of the inorganic salt A is not particularly limited. Thus, the compound represented by Formula 1, the compound represented by Formula 2, Pd(dppf)Cl 2, the efficiency of the contact reaction of inorganic salt A, accelerate the reaction speed, and further improve the efficiency of preparing the compound shown in Formula 3 using this method.

[0018] According to an embodiment of the present invention, in step (1), the following steps are included: 2 Under protection, the compound represented by Formula 1, the compound represented by Formula 2, Pd(dppf)Cl 2 and inorganic salt A solution are added to a flask containing DMF, the reaction mixture is heated to 84°C to 92°C for 10.5 to 12 hours, after the reaction, the reaction solution is cooled to room temperature, the reaction solution is filtered through diatomaceous earth and then washed with water, the aqueous phase is extracted with ethyl acetate, the organic phases are combined and washed with saturated brine, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the concentrate is purified by silica gel column chromatography with a petroleum ether / ethyl acetate mixed solvent of a volume ratio of (4 to 8): 1 to obtain a compound shown in Formula 3. Thus, the compound shown in Formula 1, the compound shown in Formula 2, Pd(dppf)Cl 2 , the efficiency of the contact reaction of inorganic salt A, accelerate the reaction speed, and further improve the efficiency of preparing the compound shown in Formula 3 using this method.

[0019] According to an embodiment of the present invention, in step (1), the compound represented by formula 1, the compound represented by formula 2, Pd(dppf)Cl 2 , inorganic salt A has a molar ratio of 1:(1.1-1.2):(0.1-0.2):15, preferably the compound represented by formula 1, the compound represented by formula 2, Pd(dppf)Cl 2 The molar ratio of , inorganic salt A is 1:1.15:0.15:15. Thus, the efficiency of preparing the compound represented by Formula 3 by the method can be further improved.

[0020] According to an embodiment of the present invention, in step (1), the inorganic salt A is at least one selected from sodium bicarbonate or potassium bicarbonate.

[0021] According to an embodiment of the present invention, in step (1), the reaction mixture is preferably heated to 88° C. to 90° C. for 11 hours.

[0022] According to an embodiment of the present invention, in step (1), the volume ratio of petroleum ether / ethyl acetate mixed solvent is preferably 6:1.

[0023] According to a specific embodiment of the present invention, in step (1), the following steps are included: 2 Under protection, the compound represented by formula 1 (24.80 g, 0.10 mol), the compound represented by formula 2 (24.84 g, 0.115 mol), Pd(dppf)Cl 2The mixture was added with 1% paraformaldehyde (10.98 g, 0.015 mol) and sodium bicarbonate solution (containing 126 g (1.5 mol) of sodium bicarbonate to prepare a 1 M solution) into a flask with DMF (250 mL). The reaction mixture was heated to 88°C-90°C for 11 hours. After the reaction, the reaction solution was cooled to room temperature. The reaction solution was filtered through diatomaceous earth and washed with water (300 mL). The aqueous phase was extracted with ethyl acetate (300 mL×2). The organic phases were combined and washed with saturated brine (300 mL). The mixture was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The concentrate was purified by silica gel column chromatography using a petroleum ether / ethyl acetate mixed solvent with a volume ratio of 6:1 to obtain the compound of formula 3 with an amount of 27.41 g and a yield of 80.8%.

[0024] According to an embodiment of the present invention, in step (2), the compound represented by formula 3 is reacted with NaOH, H 2 O 2 The contacting method is not particularly limited. Thus, the contacting reaction between the compound represented by Formula 3 and NaOH, H 2 O 2 The efficiency of the contact reaction is improved, the reaction speed is accelerated, and the efficiency of preparing the compound represented by formula 4 using this method is further improved.

[0025] According to an embodiment of the present invention, in step (2), the following steps are included: dissolving the compound represented by formula 3 in EtOH and DMSO, adding 5M NaOH aqueous solution and 30% H 2 O 2 The reaction solution was reacted at 70°C for 1 hour, cooled to room temperature and concentrated under reduced pressure to remove the organic phase solution, ethyl acetate was added to the concentrate to dissolve, and then diluted hydrochloric acid was added to wash, the aqueous phases were combined and an appropriate amount of inorganic base B aqueous solution was added to adjust the pH to 12, and then ethyl acetate was added to the aqueous phase for extraction to obtain the compound shown in formula 2. In this way, the reaction mixture of the compound shown in formula 3 and NaOH, H 2 O 2 The efficiency of the contact reaction is improved, the reaction speed is accelerated, and the efficiency of preparing the compound represented by formula 4 using this method is further improved.

[0026] According to an embodiment of the present invention, in step (2), the compound represented by formula 3 is reacted with NaOH, H 2 O 2 The molar ratio of the compound represented by formula 3 and NaOH is 1:(5.0-10.0):(8.0-12.0), preferably 2 O 2 The molar ratio of is 1:7.0:10.0. Thus, the efficiency of preparing the compound represented by Formula 4 by this method can be further improved.

[0027] According to an embodiment of the present invention, in step (2), the inorganic base B is at least one selected from sodium hydroxide or sodium potassium hydroxide.

[0028] According to a specific embodiment of the present invention, in step (2), the following steps are included: dissolving the compound represented by formula 3 (3.50 g, 10.32 mmol) in EtOH (20 mL) and DMSO (5 mL), adding 5M NaOH aqueous solution (14.4 mL, 72.24 mmol) and 30% by mass H 2 O 2 Solution (10.5mL, 103.2mmol), the reaction solution was reacted at 70℃ for 1 hour, cooled to room temperature and concentrated under reduced pressure to remove the organic phase solution, ethyl acetate (30mL) was added to the concentrate to dissolve, and then diluted hydrochloric acid (4M, 20mL×2) was added to wash, the aqueous phases were combined and an appropriate amount of sodium hydroxide aqueous solution was added to adjust the pH to 12, and ethyl acetate (40mL×2) was added to the aqueous phase for extraction to obtain the compound shown in formula 4, with an amount of 2.40g and a yield of 65.1%.

[0029] According to an embodiment of the present invention, in step (3), the contacting method of the compound represented by Formula 4, the compound represented by Formula 5, carbon disulfide, and 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) is not particularly limited. Thus, the efficiency of the contact reaction of the compound represented by Formula 4, the compound represented by Formula 5, carbon disulfide, and DBU can be improved, the reaction speed can be accelerated, and the efficiency of preparing the compound represented by Formula I using this method can be further improved.

[0030] According to an embodiment of the present invention, in step (3), the following steps are included: adding the compound represented by formula 4 and the compound represented by formula 5, carbon disulfide, DBU, H 2 O and DMSO, the reaction solution is reacted at 100°C for 2 hours, the reaction solution is cooled and washed with water, ethyl acetate is added for extraction, the organic phases are combined and washed with saturated brine, dried over anhydrous sodium sulfate, and the filtrate is concentrated under reduced pressure to obtain a solid, the solid is recrystallized with a mixed solvent of ethyl acetate and hexane, filtered, and the filter cake is dried to obtain the compound Pitobrutinib shown in Formula I. Thus, the efficiency of the contact reaction of the compound shown in Formula 4 and the compound shown in Formula 5 with carbon disulfide and DBU can be improved, the reaction speed can be accelerated, and the efficiency of preparing the compound Pitobrutinib shown in Formula I by using this method can be further improved.

[0031] According to an embodiment of the present invention, in step (3), the molar ratio of the compound represented by Formula 4, the compound represented by Formula 5, carbon disulfide, and DBU is 1: (1.02-1.1): 3: 3, and preferably the molar ratio of the compound represented by Formula 4, the compound represented by Formula 5, carbon disulfide, and DBU is 1: 1.06: 3: 3. Thus, the efficiency of preparing the compound represented by Formula I by this method can be further improved.

[0032] According to an embodiment of the present invention, in step (3), the volume ratio of ethyl acetate to hexane in the mixed solvent of ethyl acetate and hexane is (4-8):1, preferably the volume ratio of ethyl acetate to hexane is 6:1.

[0033] According to a specific embodiment of the present invention, in step (3), the following steps are included: adding the compound represented by formula 4 (2.0 g, 5.60 mmol) and the compound represented by formula 5 (1.01 g, 5.94 mmol), carbon disulfide (1.28 g, 16.8 mmol), 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) (2.56 g, 16.8 mmol), H 2 O (3 mL) and DMSO (25 mL), the reaction solution was reacted at 100 ° C for 2 hours, the reaction solution was cooled and 30 mL of water was added for washing, and ethyl acetate (30 mL×2) was added for extraction. The organic phases were combined and washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, and the filtrate was concentrated under reduced pressure to obtain a solid. The solid was recrystallized with a mixed solvent of ethyl acetate and hexane (the volume ratio of ethyl acetate to hexane was 6:1), filtered, and the filter cake was dried to obtain the compound of formula I, pitobrutinib, with an amount of 2.13 g, a yield of 79.3%, and an HPLC purity of 99.9%.

[0034] According to a specific embodiment of the present invention, the synthesis route of the compound Pitobrutinib represented by Formula I can be as follows:

[0035]

[0036] Compared with the prior art, the method for preparing the BTK small molecule inhibitor pitobrutinib of the present invention has at least the following beneficial effects:

[0037] (1) In terms of the reaction steps, in step (1), the compound represented by formula 1 and the compound represented by formula 2 undergo Suzuki coupling reaction under the condition of Pd catalyst to obtain the compound represented by formula 3; in step (2), under an alkaline environment, hydrogen peroxide is used to convert the cyano group into amide, and the compound represented by formula 3 is reacted with NaOH, H 2 O 2The contact reaction occurs to obtain a compound of Formula 4; in step (3), the nitro group (the nitro group of the compound of Formula 4) and the carboxylic acid (the carboxylic acid of the compound of Formula 5) are directly reacted to obtain the target product, Pitobrutinib.

[0038] (2) The yield of the Suzuki coupling reaction is higher than that of the general alkylation reaction, and the post-processing is convenient. When converting the cyano group to the amide, the general literature mostly uses concentrated sulfuric acid for the reaction, which is very dangerous to operate; the preparation method described in the present invention uses sodium hydroxide and hydrogen peroxide, which reduces the danger of the operation during the reaction.

[0039] (3) The preparation method described in the present invention reacts the nitro group of the compound represented by Formula 4 with the carboxylic acid of the compound represented by Formula 5 in one step to generate a product. Compared with the literature generally converting the nitro group into an amine group before reacting with the carboxylic acid, the present invention reduces the reaction steps while maintaining the same yield.

[0040] (4) In summary, the preparation method of the present invention has the advantages of simple operation, high yield, and simple purification. Compared with the previous synthetic routes, it has great advantages and is easy to industrialize, and is very suitable for large-scale industrial production. DETAILED DESCRIPTION

[0041] The embodiments of the present invention are described in detail below. The embodiments described below are exemplary and are only used to explain the present invention, and should not be construed as limiting the present invention. If no specific techniques or conditions are specified in the embodiments, the techniques or conditions described in the literature in this area or the product specifications are used. The reagents or instruments used that do not specify the manufacturer are all conventional products that can be obtained commercially.

[0042] Example 1 Synthesis of the compound represented by formula 3

[0043] N 2 Under protection, the compound represented by formula 1 (24.80 g, 0.10 mol), the compound represented by formula 2 (24.84 g, 0.115 mol), Pd(dppf)Cl 2 The mixture was added with 1% paraformaldehyde (10.98 g, 0.015 mol) and sodium bicarbonate solution (containing 126 g (1.5 mol) of sodium bicarbonate to prepare a 1 M solution) into a flask with DMF (250 mL). The reaction mixture was heated to 88°C-90°C for 11 hours. After the reaction, the reaction solution was cooled to room temperature. The reaction solution was filtered through diatomaceous earth and washed with water (300 mL). The aqueous phase was extracted with ethyl acetate (300 mL×2). The organic phases were combined and washed with saturated brine (300 mL). The mixture was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The concentrate was purified by silica gel column chromatography using a petroleum ether / ethyl acetate mixed solvent with a volume ratio of 6:1 to obtain the compound of formula 3 with an amount of 27.41 g and a yield of 80.8%.

[0044] LC-MS (APCI): m / z = 340.2 (M+1) +

[0045] Example 2 Synthesis of the compound represented by formula 3

[0046] N 2 Under protection, the compound represented by formula 1 (24.80 g, 0.10 mol), the compound represented by formula 2 (23.76 g, 0.11 mol), Pd(dppf)Cl 2 The mixture was added with 1% paraformaldehyde (7.32 g, 0.01 mol) and sodium bicarbonate solution (containing 126 g (1.5 mol) of sodium bicarbonate to make a 1 M solution) into a flask with DMF (250 mL). The reaction mixture was heated to 90°C-92°C for 10.5 hours. After the reaction, the reaction solution was cooled to room temperature. The reaction solution was filtered through diatomaceous earth and washed with water (300 mL). The aqueous phase was extracted with ethyl acetate (300 mL×2). The organic phases were combined and washed with saturated brine (300 mL). The mixture was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The concentrate was purified by silica gel column chromatography using a petroleum ether / ethyl acetate mixed solvent with a volume ratio of 4:1 to obtain the compound of formula 3. The yield was 26.23 g and the yield was 77.3%.

[0047] Example 3 Synthesis of the compound represented by formula 3

[0048] N 2 Under protection, the compound represented by formula 1 (24.80 g, 0.10 mol), the compound represented by formula 2 (25.92 g, 0.12 mol), Pd(dppf)Cl 2 The mixture was added with 14.63 g (0.02 mol) of sodium bicarbonate (14.63 g, 0.02 mol) and sodium bicarbonate solution (containing 126 g (1.5 mol) of sodium bicarbonate to prepare a 1 M solution) into a flask with DMF (250 mL). The reaction mixture was heated to 84°C to 86°C for 12 hours. After the reaction, the reaction solution was cooled to room temperature. The reaction solution was filtered through diatomaceous earth and washed with water (300 mL). The aqueous phase was extracted with ethyl acetate (300 mL×2). The organic phases were combined and washed with saturated brine (300 mL). The phases were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The concentrate was purified by silica gel column chromatography using a petroleum ether / ethyl acetate mixed solvent with a volume ratio of 8:1 to obtain the compound of formula 3 with an amount of 26.84 g and a yield of 79.1%.

[0049] Example 4 Synthesis of the compound represented by formula 3

[0050] N 2 Under protection, the compound represented by formula 1 (24.80 g, 0.10 mol), the compound represented by formula 2 (24.84 g, 0.115 mol), Pd(dppf)Cl2 The mixture was added with 1% paraformaldehyde (10.98 g, 0.015 mol) and potassium bicarbonate solution (containing 150 g (1.5 mol) of potassium bicarbonate to prepare a 1 M solution) into a flask with DMF (250 mL). The reaction mixture was heated to 88°C-90°C for 11 hours. After the reaction, the reaction solution was cooled to room temperature. The reaction solution was filtered through diatomaceous earth and washed with water (300 mL). The aqueous phase was extracted with ethyl acetate (300 mL×2). The organic phases were combined and washed with saturated brine (300 mL). The phases were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The concentrate was purified by silica gel column chromatography using a petroleum ether / ethyl acetate mixed solvent with a volume ratio of 6:1 to obtain the compound of formula 3. The yield was 27.14 g and the yield was 80.0%.

[0051] Comparative Example 1: Synthesis of the compound represented by Formula 3

[0052] N 2 Under protection, the compound represented by formula 1 (24.80 g, 0.10 mol), the compound represented by formula 2 (21.60 g, 0.10 mol), Pd(dppf)Cl 2 The mixture was added with 1% paraformaldehyde (5.85 g, 0.008 mol) and sodium bicarbonate solution (containing 84 g (1.0 mol) of sodium bicarbonate to prepare a 1 M solution) into a flask with DMF (250 mL). The reaction mixture was heated to 88°C-90°C for 11 hours. After the reaction, the reaction solution was cooled to room temperature. The reaction solution was filtered through diatomaceous earth and washed with water (300 mL). The aqueous phase was extracted with ethyl acetate (300 mL×2). The organic phases were combined and washed with saturated brine (300 mL). The phases were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The concentrate was purified by silica gel column chromatography using a petroleum ether / ethyl acetate mixed solvent with a volume ratio of 6:1 to obtain the compound of formula 3. The yield was 24.56 g and the yield was 72.4%.

[0053] Comparative Example 2: Synthesis of the compound represented by Formula 3

[0054] N 2 Under protection, the compound represented by formula 1 (24.80 g, 0.10 mol), the compound represented by formula 2 (29.16 g, 0.135 mol), Pd(dppf)Cl 2The mixture was added with 100.8 g (1.2 mol) of sodium bicarbonate (18.29 g, 0.025 mol) and a 1 M solution of sodium bicarbonate (100.8 g (1.2 mol) of sodium bicarbonate) into a flask with DMF (250 mL). The reaction mixture was heated to 88°C to 90°C for 11 hours. After the reaction, the reaction solution was cooled to room temperature. The reaction solution was filtered through diatomaceous earth and washed with water (300 mL). The aqueous phase was extracted with ethyl acetate (300 mL × 2). The organic phases were combined and washed with saturated brine (300 mL). The phases were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The concentrate was purified by silica gel column chromatography using a petroleum ether / ethyl acetate mixed solvent with a volume ratio of 6:1 to obtain the compound of formula 3 with an amount of 25.04 g and a yield of 73.8%.

[0055] Example 5 Synthesis of the compound represented by formula 4

[0056] The compound of formula 3 (3.50 g, 10.32 mmol) was dissolved in EtOH (20 mL) and DMSO (5 mL), and 5 M NaOH aqueous solution (14.4 mL, 72.24 mmol) and 30% H 2 O 2 Solution (10.5mL, 103.2mmol), the reaction solution was reacted at 70℃ for 1 hour, cooled to room temperature and concentrated under reduced pressure to remove the organic phase solution, ethyl acetate (30mL) was added to the concentrate to dissolve, and then diluted hydrochloric acid (4M, 20mL×2) was added to wash, the aqueous phases were combined and an appropriate amount of sodium hydroxide aqueous solution was added to adjust the pH to 12, and ethyl acetate (40mL×2) was added to the aqueous phase for extraction to obtain the compound shown in formula 4, with an amount of 2.40g and a yield of 65.1%.

[0057] LC-MS (APCI): m / z = 358.2 (M+1) + .

[0058] Example 6 Synthesis of the compound represented by formula 4

[0059] The compound of formula 3 (3.50 g, 10.32 mmol) was dissolved in EtOH (20 mL) and DMSO (5 mL), and 5 M NaOH aqueous solution (10.3 mL, 51.60 mmol) and 30% H 2 O 2Solution (8.7mL, 82.56mmol), the reaction solution was reacted at 70℃ for 1 hour, cooled to room temperature and concentrated under reduced pressure to remove the organic phase solution, ethyl acetate (30mL) was added to the concentrate to dissolve, and then diluted hydrochloric acid (4M, 20mL×2) was added to wash, the aqueous phases were combined and an appropriate amount of sodium hydroxide aqueous solution was added to adjust the pH to 12, and ethyl acetate (40mL×2) was added to the aqueous phase for extraction to obtain the compound shown in formula 4, with an amount of 2.32g and a yield of 63.0%.

[0060] Example 7 Synthesis of the compound represented by formula 4

[0061] The compound of formula 3 (3.50 g, 10.32 mmol) was dissolved in EtOH (20 mL) and DMSO (5 mL), and 5 M NaOH aqueous solution (20.6 mL, 103.2 mmol) and 30% H 2 O 2 Solution (12.6mL, 123.8mmol), the reaction solution was reacted at 70℃ for 1 hour, cooled to room temperature and concentrated under reduced pressure to remove the organic phase solution, ethyl acetate (30mL) was added to the concentrate to dissolve, and then diluted hydrochloric acid (4M, 20mL×2) was added to wash, the aqueous phases were combined and an appropriate amount of sodium hydroxide aqueous solution was added to adjust the pH to 12, and ethyl acetate (40mL×2) was added to the aqueous phase for extraction to obtain the compound shown in formula 4, with an amount of 2.37g and a yield of 64.3%.

[0062] Example 8 Synthesis of the compound represented by formula 4

[0063] The compound of formula 3 (3.50 g, 10.32 mmol) was dissolved in EtOH (20 mL) and DMSO (5 mL), and 5 M NaOH aqueous solution (14.4 mL, 72.24 mmol) and 30% H 2 O 2 Solution (10.5mL, 103.2mmol). The reaction solution was reacted at 70°C for 1 hour, cooled to room temperature and concentrated under reduced pressure to remove the organic phase solution, ethyl acetate (30mL) was added to the concentrate to dissolve, and then diluted hydrochloric acid (4M, 20mL×2) was added to wash, and the aqueous phases were combined and added with an appropriate amount of potassium hydroxide aqueous solution to adjust the pH to 12, and then ethyl acetate (40mL×2) was added to the aqueous phase for extraction to obtain the compound shown in formula 4, with an amount of 2.35g and a yield of 63.7%.

[0064] Example 9 Synthesis of Pitobrutinib

[0065] In a 50 ml sealed tube, the compound represented by formula 4 (2.0 g, 5.60 mmol) and the compound represented by formula 5 (1.01 g, 5.94 mmol), carbon disulfide (1.28 g, 16.8 mmol), 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) (2.56 g, 16.8 mmol), H 2 O (3 mL) and DMSO (25 mL), the reaction solution was reacted at 100 ° C for 2 hours, the reaction solution was cooled and 30 mL of water was added for washing, and ethyl acetate (30 mL×2) was added for extraction. The organic phases were combined and washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, and the filtrate was concentrated under reduced pressure to obtain a solid. The solid was recrystallized with a mixed solvent of ethyl acetate and hexane (the volume ratio of ethyl acetate to hexane was 6:1), filtered, and the filter cake was dried to obtain the compound of formula I, pitobrutinib, with an amount of 2.13 g, a yield of 79.3%, and an HPLC purity of 99.9%.

[0066] LC-MS (ES) m / z = 480.2 (M+1) + .

[0067] Example 10 Synthesis of Pitobrutinib

[0068] In a 50 ml sealed tube, the compound represented by formula 4 (2.0 g, 5.60 mmol) and the compound represented by formula 5 (0.97 g, 5.71 mmol), carbon disulfide (1.28 g, 16.8 mmol), 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) (2.56 g, 16.8 mmol), H 2 O (3 mL) and DMSO (25 mL), the reaction solution was reacted at 100 ° C for 2 hours, the reaction solution was cooled and 30 mL of water was added for washing, and ethyl acetate (30 mL×2) was added for extraction. The organic phases were combined and washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, and the filtrate was concentrated under reduced pressure to obtain a solid. The solid was recrystallized with a mixed solvent of ethyl acetate and hexane (the volume ratio of ethyl acetate to hexane was 4:1), filtered, and the filter cake was dried to obtain the compound of formula I, pitobrutinib, with an amount of 2.08 g, a yield of 77.6%, and an HPLC purity of 99.6%.

[0069] Example 11 Synthesis of Pitobrutinib

[0070] In a 50 ml sealed tube, the compound represented by formula 4 (2.0 g, 5.60 mmol) and the compound represented by formula 5 (1.05 g, 6.16 mmol), carbon disulfide (1.28 g, 16.8 mmol), 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) (2.56 g, 16.8 mmol), H2 O (3 mL) and DMSO (25 mL), the reaction solution was reacted at 100 ° C for 2 hours, the reaction solution was cooled and washed with 30 mL of water, and then extracted with ethyl acetate (30 mL×2), the organic phases were combined and washed with saturated brine (30 mL), and dried over anhydrous sodium sulfate. The filtrate was concentrated under reduced pressure to obtain a solid, and the solid was recrystallized with a mixed solvent of ethyl acetate and hexane (the volume ratio of ethyl acetate to hexane was 8:1), filtered, and the filter cake was dried to obtain the compound of formula I, pitobrutinib, with an amount of 2.10 g, a yield of 78.3%, and an HPLC purity of 99.5%.

[0071] Comparative Example 3: Synthesis of Pitobrutinib

[0072] In a 50 ml sealed tube, add the compound represented by formula 4 (2.0 g, 5.60 mmol) and the compound represented by formula 5 (0.95 g, 5.60 mmol), carbon disulfide (1.28 g, 16.8 mmol), 1,8-diazabicyclo[5.4.0]undec-7-ene (3.41 g, 22.4 mmol), H 2 O (3 mL) and DMSO (25 mL), the reaction solution was reacted at 100 ° C for 2 hours, the reaction solution was cooled and 30 mL of water was added for washing, and ethyl acetate (30 mL×2) was added for extraction. The organic phases were combined and washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, and the filtrate was concentrated under reduced pressure to obtain a solid. The solid was recrystallized with a mixed solvent of ethyl acetate and hexane (the volume ratio of ethyl acetate to hexane was 6:1), filtered, and the filter cake was dried to obtain the compound of formula I, pitobrutinib, with an amount of 1.92 g, a yield of 71.5%, and an HPLC purity of 98.6%.

[0073] Comparative Example 4: Synthesis of Pitobrutinib

[0074] In a 50 ml sealed tube, add the compound represented by formula 4 (2.0 g, 5.60 mmol) and the compound represented by formula 5 (1.14 g, 6.72 mmol), carbon disulfide (1.71 g, 22.4 mmol), 1,8-diazabicyclo[5.4.0]undec-7-ene (2.98 g, 19.6 mmol), H 2O (3 mL) and DMSO (25 mL), the reaction solution was reacted at 100 ° C for 2 hours, the reaction solution was cooled and 30 mL of water was added for washing, and ethyl acetate (30 mL×2) was added for extraction. The organic phases were combined and washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, and the filtrate was concentrated under reduced pressure to obtain a solid. The solid was recrystallized with a mixed solvent of ethyl acetate and hexane (the volume ratio of ethyl acetate to hexane was 8:1), filtered, and the filter cake was dried to obtain the compound of formula I, pitobrutinib, with an amount of 1.95 g, a yield of 72.6%, and an HPLC purity of 99.0%.

[0075] In the description of this specification, the description with reference to the terms "one embodiment", "some embodiments", "example", "specific example", or "some examples" etc. means that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present invention. In this specification, the schematic representations of the above terms do not necessarily refer to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described may be combined in any one or more embodiments or examples in a suitable manner. In addition, those skilled in the art may combine and combine the different embodiments or examples described in this specification and the features of the different embodiments or examples, without contradiction.

[0076] Although the embodiments of the present invention have been shown and described above, it is to be understood that the above embodiments are exemplary and are not to be construed as limitations of the present invention. A person skilled in the art may change, modify, replace and vary the above embodiments within the scope of the present invention.

Claims

1. A method for preparing Pitobrutinib, characterized in that: include: (1) contacting the compound represented by Formula 1, the compound represented by Formula 2, Pd(dppf)Cl2, and an inorganic salt A to obtain a compound represented by Formula 3; (2) contacting the compound represented by Formula 3 with NaOH and H2O2 to obtain the compound represented by Formula 4; (3) contacting the compound represented by Formula 4 and the compound represented by Formula 5 with carbon disulfide and DBU to obtain the compound represented by Formula I, Pitobrutinib, In step (1), the inorganic salt A is at least one selected from sodium bicarbonate or potassium bicarbonate.

2. The method according to claim 1, characterized in that In step (1), the following steps are included: under N2 protection, the compound represented by formula 1, the compound represented by formula 2, Pd(dppf)Cl2 and inorganic salt A solution are added to a flask containing DMF, the reaction mixture is heated to 84°C to 92°C for reaction for 10.5 hours to 12 hours, after the reaction, the reaction solution is cooled to room temperature, the reaction solution is filtered through diatomaceous earth and then washed with water, the aqueous phase is extracted with ethyl acetate, the organic phases are combined and then washed with saturated brine, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the concentrate is purified by silica gel column chromatography using a petroleum ether / ethyl acetate mixed solvent with a volume ratio of (4 to 8):1 to obtain a compound represented by formula 3.

3. The method according to claim 2, characterized in that In step (1), the molar ratio of the compound represented by Formula 1, the compound represented by Formula 2, Pd(dppf)Cl2, and the inorganic salt A is 1:(1.1-1.2):(0.1-0.2):15, and preferably the molar ratio of the compound represented by Formula 1, the compound represented by Formula 2, Pd(dppf)Cl2, and the inorganic salt A is 1:1.15:0.15:

15.

4. The method according to claim 2, characterized in that: In step (1), the reaction mixture is preferably heated to 88°C to 90°C for 11 hours; Optionally, in step (1), the volume ratio of petroleum ether / ethyl acetate mixed solvent is preferably 6:

1.

5. The method according to claim 1, characterized in that In step (2), the following steps are included: dissolving the compound shown in formula 3 in EtOH and DMSO, adding 5M NaOH aqueous solution and 30% H2O2 solution by mass, reacting the reaction solution at 70°C for 1 hour, cooling to room temperature and concentrating under reduced pressure to remove the organic phase solution, adding ethyl acetate to the concentrate to dissolve, then adding dilute hydrochloric acid to wash, combining the aqueous phases, adding an appropriate amount of inorganic base B aqueous solution, adjusting the pH to 12, and then adding ethyl acetate to the aqueous phase for extraction to obtain the compound shown in formula 2.

6. The method according to claim 5, characterized in that In step (2), the molar ratio of the compound represented by formula 3 to NaOH and H2O2 is 1:(5.0-10.0):(8.0-12.0), and preferably the molar ratio of the compound represented by formula 3 to NaOH and H2O2 is 1:7.0:10.

0.

7. The method according to claim 1, characterized in that In step (2), the inorganic base B is at least one selected from sodium hydroxide or sodium potassium hydroxide.

8. The method according to claim 1, characterized in that In step (3), the following steps are included: adding the compound represented by formula 4 and the compound represented by formula 5, carbon disulfide, DBU, H2O and DMSO into a sealed tube, reacting the reaction solution at 100°C for 2 hours, adding water to wash the reaction solution after cooling, adding ethyl acetate to extract, combining the organic phases, washing with saturated brine, drying over anhydrous sodium sulfate, and concentrating the filtrate under reduced pressure to obtain a solid, recrystallizing the solid with a mixed solvent of ethyl acetate and hexane, filtering, and drying the filter cake to obtain the compound represented by formula I, pirotibrutinib.

9. The method according to claim 8, characterized in that In step (3), the molar ratio of the compound represented by formula 4, the compound represented by formula 5, carbon disulfide, and DBU is 1:(1.02-1.1):3:3, preferably the molar ratio of the compound represented by formula 4, the compound represented by formula 5, carbon disulfide, and DBU is 1:1.06:3:3; Optionally, in step (3), the volume ratio of ethyl acetate to hexane in the mixed solvent of ethyl acetate and hexane is (4-8):1, preferably the volume ratio of ethyl acetate to hexane is 6:

1.

10. The method according to claim 1, characterized in that In step (1), the following steps are included: under N2 protection, the compound represented by formula 1 (24.80 g, 0.10 mol), the compound represented by formula 2 (24.84 g, 0.115 mol), Pd(dppf)Cl2 (10.98 g, 0.015 mol) and sodium bicarbonate solution (containing 126 g (1.5 mol) of sodium bicarbonate, prepared into a 1 M solution) are added to a flask of DMF (250 mL), and the reaction mixture is heated to The mixture was reacted at 88°C to 90°C for 11 hours. After the reaction, the reaction solution was cooled to room temperature, filtered through diatomaceous earth and washed with water (300 mL). The aqueous phase was extracted with ethyl acetate (300 mL×2). The organic phases were combined and washed with saturated brine (300 mL). The organic phases were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The concentrate was purified by silica gel column chromatography using a mixed solvent of petroleum ether / ethyl acetate in a volume ratio of 6:1 to obtain the compound of formula 3. The yield was 27.41 g and the yield was 80.8%. In step (2), the following steps are included: dissolving the compound represented by formula 3 (3.50 g, 10.32 mmol) in EtOH (20 mL) and DMSO (5 mL), adding 5M NaOH aqueous solution (14.4 mL, 72.24 mmol) and 30% H2O2 solution (10.5 mL, 103.2 mmol), reacting the reaction solution at 70°C for 1 hour, cooling to room temperature and concentrating under reduced pressure to remove the organic phase solution, adding ethyl acetate (30 mL) to the concentrate to dissolve, then adding dilute hydrochloric acid (4 M, 20 mL×2) to wash, combining the aqueous phases, adding an appropriate amount of sodium hydroxide aqueous solution, adjusting the pH to 12, and then adding ethyl acetate (40 mL×2) to the aqueous phase for extraction to obtain the compound represented by formula 4, with an amount of 2.40 g and a yield of 65.1%; In step (3), the following steps are included: adding the compound represented by formula 4 (2.0 g, 5.60 mmol) and the compound represented by formula 5 (1.01 g, 5.94 mmol), carbon disulfide (1.28 g, 16.8 mmol), 1,8-diazabicyclo[5.4.0]undec-7-ene (2.56 g, 16.8 mmol), H2O (3 mL) and DMSO (25 mL) into a 50 ml sealed tube, and reacting the reaction solution at 100°C for 2 hours After the reaction solution was cooled, 30 mL of water was added for washing, and ethyl acetate (30 mL×2) was added for extraction. The organic phases were combined and washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, and the filtrate was concentrated under reduced pressure to obtain a solid. The solid was recrystallized with a mixed solvent of ethyl acetate and hexane (the volume ratio of ethyl acetate to hexane was 6:1), filtered, and the filter cake was dried to obtain the compound of formula I, pitobrutinib, with an yield of 2.13 g, a yield of 79.3%, and a HPLC purity of 99.9%.

Citation Information

Patent Citations

  • BTK inhibitor ring derivative as well as preparation method and pharmaceutical application thereof

    CN113999233A

  • Compounds useful as kinase inhibitors

    CN114621146A

  • Amide derivative and application thereof in medicine

    CN114920690A

  • Process and intermediates for preparation of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido) methyl) phenyl)-1-(1, 1, 1-trifluoropropyl-2-yl)-1h-pyrazol-4-carboxamide

    CN116323553A

  • Cycloalkyl or heterocyclic group substituted heteroaryl compound as well as composition and application thereof

    CN116693458A